Skip to main content
A new antidepressant that combines selective serotonin reuptake inhibition with partial agonism of the 5-HT1A receptor has been approved by the FDA. Vilazodone is marketed by Trovis Pharmaceuticals as Viibryd(TM).

Vilazodone Hydrochloride Tablets (Viibryd™)

March 15, 2011

A new antidepressant that combines selective serotonin reuptake inhibition with partial agonism of the 5-HT1A receptor has been approved by the FDA. Vilazodone is marketed by Trovis Pharmaceuticals as Viibryd(TM).